PE20151526A1 - Tratamiento de formas progresivas de esclerosis multiple con laquinimod - Google Patents
Tratamiento de formas progresivas de esclerosis multiple con laquinimodInfo
- Publication number
- PE20151526A1 PE20151526A1 PE2015001745A PE2015001745A PE20151526A1 PE 20151526 A1 PE20151526 A1 PE 20151526A1 PE 2015001745 A PE2015001745 A PE 2015001745A PE 2015001745 A PE2015001745 A PE 2015001745A PE 20151526 A1 PE20151526 A1 PE 20151526A1
- Authority
- PE
- Peru
- Prior art keywords
- laquinimod
- multiple sclerosis
- treatment
- progressive forms
- human subject
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004577 laquinimod Drugs 0.000 title abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 230000000750 progressive effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US201361911106P | 2013-12-03 | 2013-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151526A1 true PE20151526A1 (es) | 2015-11-20 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001745A PE20151526A1 (es) | 2013-02-15 | 2014-02-13 | Tratamiento de formas progresivas de esclerosis multiple con laquinimod |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (enExample) |
| EP (1) | EP2956137A4 (enExample) |
| JP (1) | JP2016510343A (enExample) |
| KR (1) | KR20150119227A (enExample) |
| CN (1) | CN105163737A (enExample) |
| AU (1) | AU2014216199A1 (enExample) |
| BR (1) | BR112015019564A2 (enExample) |
| CA (1) | CA2900503A1 (enExample) |
| CL (1) | CL2015002181A1 (enExample) |
| EA (1) | EA201591507A1 (enExample) |
| HK (2) | HK1218254A1 (enExample) |
| IL (1) | IL240014A0 (enExample) |
| MX (1) | MX2015010296A (enExample) |
| PE (1) | PE20151526A1 (enExample) |
| SG (1) | SG11201505818WA (enExample) |
| TW (1) | TW201442709A (enExample) |
| UY (1) | UY35328A (enExample) |
| WO (1) | WO2014127139A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| CA2945978A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2016059571A1 (en) * | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| LT3506921T (lt) | 2016-08-31 | 2023-08-10 | Mapi Pharma Ltd | Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato |
| BR112019017724A2 (pt) * | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| EP4178675A4 (en) * | 2020-07-09 | 2024-08-07 | Oklahoma Medical Research Foundation | BIOMARKERS FOR THE IDENTIFICATION OF RELAPSES IN MULTIPLE SCLEROSIS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| UA96449C2 (en) * | 2006-06-12 | 2011-11-10 | Тева Фармасьютикл Индастриз, Лтд. | Stable laquinimod preparations |
| PT2187882E (pt) * | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| CA2747235C (en) * | 2008-12-11 | 2021-02-09 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| WO2010147665A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| KR20130124518A (ko) * | 2010-12-07 | 2013-11-14 | 테바 파마슈티컬 인더스트리즈 리미티드 | 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도 |
| JP2014521659A (ja) * | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
| CA2945978A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
-
2014
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016510343A (ja) | 2016-04-07 |
| AU2014216199A1 (en) | 2015-09-03 |
| IL240014A0 (en) | 2015-09-24 |
| HK1218254A1 (zh) | 2017-02-10 |
| TW201442709A (zh) | 2014-11-16 |
| CL2015002181A1 (es) | 2016-06-03 |
| US20140235670A1 (en) | 2014-08-21 |
| EA201591507A1 (ru) | 2015-12-30 |
| CN105163737A (zh) | 2015-12-16 |
| SG11201505818WA (en) | 2015-08-28 |
| EP2956137A4 (en) | 2016-08-03 |
| HK1218251A1 (zh) | 2017-02-10 |
| BR112015019564A2 (pt) | 2017-07-18 |
| MX2015010296A (es) | 2016-05-05 |
| KR20150119227A (ko) | 2015-10-23 |
| WO2014127139A1 (en) | 2014-08-21 |
| US20180064702A1 (en) | 2018-03-08 |
| EP2956137A1 (en) | 2015-12-23 |
| UY35328A (es) | 2014-09-30 |
| CA2900503A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| EA201690753A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| MX365321B (es) | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| MX2016002308A (es) | Tratamiento del mieloma multiple. | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| AR094809A1 (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| UY35748A (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| HK1227285A1 (en) | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |